Publication: Compuestos multidiana derivados de inhibidores de la RHO-Quinasa(Rock) con potencial actividad frente a enfermedades neurodegenerativas
Loading...
Official URL
Full text at PDC
Publication Date
2022-09-05
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
Los avances en la terapéutica han aumentado considerablemente la esperanza de vida y, por tanto, la proporción de población anciana, lo que conlleva la aparición de nuevas patologías que se dan en edades avanzadas, como es el caso de las enfermedades neurodegenerativas. La enfermedad de Alzheimer, la de Parkinson o la esclerosis lateral amiotrófica (ELA) son algunos ejemplos de este tipo de enfermedades, cuya relevancia se basa en su prevalencia dentro de este grupo de población, y en la ausencia de un tratamiento curativo o realmente efectivo. Este tipo de enfermedades suelen tener en común una etiología múltiple y complicada, ya que tienden a ser patologías que incluyen alteraciones en varios procesos fisiológicos, normalmente asociadas al envejecimiento. Esta compleja red de alteraciones hace que el desarrollo de fármacos basados en la estrategia clásica de “un fármaco-una diana” no haya logrado una terapia plenamente funcional. Frente a este problema ha surgido una nueva estrategia, la estrategia de fármacos dirigidos a varias dianas, o fármacos multidiana, que contempla que una única entidad química sea capaz de interactuar con varias dianas, de modo que el efecto terapéutico se dé a través de varias vías complementarias, de forma sinérgica...
The new advances in therapeutics have increased life expectancy, and therefore the percentage of elder people, leading to an increase in age-related pathologies such as neurodegenerative disorders. Alzheimer’s disease, Parkinson disease and amyotrophic lateral sclerosis (ALS) are some examples of these disorders, which are particularly relevant in drug discovery due to the absence of effective treatments.These age-related disorders have multiple and complex etiologies, since several physiological processes are altered at the same time, leading to a complex network of disturbances. In this scenario, the classical “one drug-one target” approach to drug discovery is not suitable to achieve an efficient therapy. The new approach of multiple target-directed ligands, which proposes that one chemical entity might be able to interact with several targets in a synergistic fashion, seems more promising...
The new advances in therapeutics have increased life expectancy, and therefore the percentage of elder people, leading to an increase in age-related pathologies such as neurodegenerative disorders. Alzheimer’s disease, Parkinson disease and amyotrophic lateral sclerosis (ALS) are some examples of these disorders, which are particularly relevant in drug discovery due to the absence of effective treatments.These age-related disorders have multiple and complex etiologies, since several physiological processes are altered at the same time, leading to a complex network of disturbances. In this scenario, the classical “one drug-one target” approach to drug discovery is not suitable to achieve an efficient therapy. The new approach of multiple target-directed ligands, which proposes that one chemical entity might be able to interact with several targets in a synergistic fashion, seems more promising...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, leída el 18-05-2022